Real-world evaluation of compliance and preference in Alzheimer’s disease treatment
Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 Shelley diTommaso,8 Ozgur Yuksel81Division of Behavioral Neurology, Department of Neurology, 2Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine,...
Guardado en:
Autores principales: | Pai MC, Aref H, Bassil N, Kandiah N, Lee JH, Srinivasan AV, diTommaso S, Yuksel O |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e115521c071045b88a727d093dcf45db |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara C, et al.
Publicado: (2021) -
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Ben Seltzer
Publicado: (2009) -
Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Noll Campbell, et al.
Publicado: (2008) -
A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy
por: Wattmo C, et al.
Publicado: (2013) -
Antagonism of morphine-induced central respiratory depression by donepezil in the anesthetized rabbit
por: TSUJITA,MIKI, et al.
Publicado: (2007)